KT-253

N/A

Report date: 2024/06/20 17:08:15
NME

Base Information

Drug NameKT-253
Drug Alias NameKT-253
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 degraders
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsSolid tumoursLymphomaLeukemia, Myeloid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphomaLeukemia, Myeloid +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A